A Q&A with Thomas Müller, adaptive licensing sceptic from Germany’s health technology assessment body, the G-BA
This article was originally published in SRA
Executive Summary
German health technology assessor Thomas Müller put the cat among the pigeons recently when he suggested that adaptive licensing – under which certain new drugs would be approved earlier on in the development process than at present and on the basis of less evidence – could be perceived as a lowering of standards at the European Medicines Agency.